Cytapheresis in inflammatory bowel diseases: Current evidence and perspectives

Digestion

Volumn 77, Issue 2, 2008, Pages 96-107

  Danese, Silvio ^a,c   Angelucci, Erika ^b   Stefanelli, Tommaso ^a   Omodei, Paolo ^a   Luigiano, Carmelo ^a   Finazzi, Silvia ^a   Pagano, Nico ^a   Repici, Alessandro ^a   Vecchi, Maurizio ^a   Malesci, Alberto ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CELLULOSE ACETATE; CYTOKINE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; PREDNISOLONE;

ADSORPTION; CLINICAL TRIAL; COLITIS; CORTICOSTEROID THERAPY; CROHN DISEASE; CYTAPHERESIS; CYTOKINE PRODUCTION; DRUG DOSE INCREASE; DRUG MEGADOSE; FILTER; GRANULOCYTE; HUMAN; ILEITIS; LEUKOCYTAPHERESIS; MEDICAL INSTRUMENTATION; MONOCYTE; PATIENT SAFETY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TREATMENT OUTCOME; ULCERATIVE COLITIS;

COLITIS, ULCERATIVE; CROHN DISEASE; CYTAPHERESIS; HUMANS;

EID: 42349109788     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000122473     Document Type: Review

References (69)

1. Present DH: How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis 2000;6:48:57.
2. Nikolaus S, Bauditz J, Gionchetti P: Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin-10 during intestinal inflammation. Gut 1998;42:470-476.
3. Fiocchi C: Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115:182-205.
4. Bicks RO, Groshart KD: Editorial: the current status of T-lymphocyte apheresis treatment of Crohn's disease. J Clin Gastroenterol 1989;11:136-138.
5. Saniabadi AR, Hanai H, Takeuchi K, et al: Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial 2003;7:48-59.
6. Shirokaze J: Leukocytapheresis using a leukocyte removal filter. Ther Apher 2002;6:261-266.
7. Shibata H, Kuriyama T, Yamawaki N: Cell-sorba. Ther Apher Dial 2003;7:44-47.
8. Ashizuka S, Nishiura R, Ishikawa N, et al: Leukocytapheresis for ulcerative colitis: a comparative study of anticoagulant (nafamostat mesilate vs. dalteparin sodium) for reducing clinical complications. Ther Apher Dial 2006;10:54-58.
9. Hiraishi K, Takeda Y, Saniabadi A, et al: Studies on the mechanisms of leukocytes adhesion to cellulose acetate beads: an in vitro model to assess the efficacy of cellulose acetate carrier-based granulocyte and monocyte adsorptive apheresis. Ther Apher Dial 2003;7:334-340.
10. D'Arrigo C, Candal-Couto JJ, Greer M, et al: Human neutrophil Fc receptor mediated adhesion under flow: a hallow fiber model of intravascular arrest. Clin Exp Immunol 1994;100:173-179.
11. Kashiwagi N, Saniabadi A, Shimoyama T: Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci 2002;47:1334-1341.
12. Shimoyama T, Sawada K, Saniabadi A: Safety and efficacy of granulocyte and monocyte apheresis in patients with active ulcerative colitis. J Clin Apher 2001;16:1-9.
13. Hanai H, Watanabe F, Saniabadi A, et al: Therapeutic efficacy of granulocyte and monocyte adsorption apheresis in severe active ulcerative colitis. Dig Dis Sci 2002;47:2349-2353.
14. Andoh A, Tsujikawa T, Inatomi O, et al: Suppression of inflammatory cytokine secretion by granulocyte/monocyte adsorptive apheresis in active ulcerative colitis. Ther Apher Dial 2005;9:123-127.
15. Rembacken BJ, Newbould HE, Richards SJ, et al: Granulocyte apheresis in inflammatory bowel disease: possible mechanism of effect. Ther Apher 1998;2:93-96.
16. Kashiwagi N, Hirata I, Kasukawa R: Granulocyte/active oxygen and modulation of the inflammation response. J Act Oxyg Free Rad 1995;6:1-25.
17. Jutila MA, Rott I, Berg EL, et al: Function and regulation of the neutrophil MEL-14 antigen in vivo: comparison LFA-1 and Mac-1. J Immunol 1989;143:3318-3324.
18. Dransfield I, Stocks SG, Haslett C: Regulation of cell adhesion molecule expression and function associated with neutrophil apoptosis. Blood 1995;85:3246-3253.
19. Takeda Y, Hiraishi K, Takeda H, et al: Cellulose acetate beads induce release of interleukin-1 receptor antagonist, but not tumor necrosis factor-α or interleukin-1β in human peripheral blood. Inflam Res 2003;52:287-290.
20. Sakimura K, Omori T, Iwashita E, et al: Clinical response is associated with elevated plasma interleukin-1 receptor antagonist during selective granulocyte and monocyte apheresis in patients with ulcerative colitis. Dig Dis Sci 2006;51:1525-1531.
21. Saniabadi AR, Hanai H, Suzuki Y, et al: Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy? J Clin Apher 2005;20:171-184.
22. Hanai H, Watanabe F, Yamada M, et al: Correlation of serum soluble TNF-α receptor I and II levels with disease activity in patients with ulcerative colitis. Am J Gastroenterol 2004;99:1532-1538.
23. Suzuki Y, Aoki H, Nakamura K, et al: Adacolumn selective leukocytapheresis in patients with active ulcerative colitis: clinical efficacy, effects on plasma interleukin-8 and the expression of Toll-like receptors on granulocytes (abstract). Gastroenterology 2006;130(Suppl 2):A-657.
24. Fukunaga K, Yokoyama Y, Fukuda Y, et al: Demonstration of low regulatory CD25high+CD4+ and high pro-inflammatory CD28-CD4+ T-cells subsets in patients with ulcerative colitis: modified by selective granulocyte and monocyte adsorption apheresis (abstract). Gut 2006;55(Suppl V):A-125.
25. Hanai H, Iida T, Watanabe F, et al: Elevated pro-inflammatory monocytes, CD14+CD16+ in the peripheral blood of patients with active inflammatory bowel disease decreases markedly during Adacolumn leukocytapheresis therapy (abstract). Gut 2006;55(Suppl V):A-104.
26. Shimoyama T, Sawada K, Tanaka T, et al: Granulocyte and monocyte apheresis with the G-1 column in the treatment of patients with active ulcerative colitis (in Japanese). Jpn J Apher 1999;18:117-131.
27. Suzuki Y, Yoshimura N, Saitoh Y, et al: Granulocyte and monocyte adsorptive apheresis in a case with severe ulcerative colitis unresponsive to conventional medication. J Clin Apher 2003;18:40-42.
28. Nakamura T, Suzuki Y, Koide H, et al: Granulocyte and monocyte adsorption apheresis in a patient with antiglomerular basement membrane glomerulonephritis and active ulcerative colitis. Am J Med Sci 2003;325:296-298.
29. Fukunaga K, Sawada K, Fukuda Y, et al: Extracorporeal monocyte granulocytapheresis was effective for a patient of erythema nodosum concomitant with ulcerative colitis. Ther Apher Dial 2003;7:122-126.
30. Premchand P, Takeuchi K, Byarnason I: Granulocyte, macrophage, monocyte apheresis for refractory ulcerative proctitis. Eur J Gastroenterol Hepatol 2004;16:943-945.
31. Hanai H, Watanabe F, Takeuchi K, et al: Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol 2003;1:28-35.
32. Suzuki Y, Yoshimura N, Saniabadi AR, et al: Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naive patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci 2004;49:565-571.
33. Naganuma M, Funakoshi F, Sakuraba A, et al: Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis 2004;10:251-257.
34. Hanai H, Watanabe F, Yamada M, et al: Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion 2004;70:36-44.
35. Yamamoto T, Umegae S, Kitagawa T, et al: Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study. Aliment Pharmacol Ther 2004;20:783-792.
36. Domenech E, Hinojosa H, Esteve-Comes M, et al: Granulocyteapheresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther 2004;20:1347-1352.
37. Kanke K, Nakano M, Hiraishi H, et al: Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig Liver Dis 2004;36:811-817.
38. Kim HJ, Kim JS, Han DS, et al: Granulocyte and monocyte adsorption apheresis in Korean conventional treatment-refractory patients with active ulcerative colitis: a prospective open-label multicenter study. Korean J Gastroenterol 2005;45:34-44.
39. Kruis W, Dignass A, Steinhagen-Thiessen E, et al: Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid-refractory ulcerative colitis. World J Gastroenterol 2005;11:7001-7006.
40. D'Ovidio V, Aratari A, Viscido A, et al: Mucosal features and granulocyte-monocyte apheresis in steroid-dependent/refractory ulcerative colitis. Dig Liver Dis 2006;38:389-394.
41. Bresci G, Parisi G, Bertoni M, et al: Treatment of active steroid-refractory inflammatory bowel diseases with granulocytapheresis: our experience with a prospective study. World J Gastroenterol 2006;12:2201-2204.
42. Sands BE, Sandborn WJ, Wolf DC, et al: Pilot feasibility studies leukocytapheresis with the Adacolumn apheresis system in patients with active ulcerative colitis and Crohn's disease. J Clin Gastroenterol 2006;40:482-489.
43. Sakuraba A, Inoue N, Kohgo Y, et al: A multicenter, randomized, controlled trial between weekly and semiweekly treatment with granulocyte and monocyte adsorption apheresis for active ulcerative colitis (abstract). Gastroenterology 2005;128(Suppl 2):A-585.
44. Tanaka T, Okanobu H, Saniabadi AR, et al: Efficacy of Adacolumn-selective leukocytapheresis in patients with steroid-naive and steroid-dependent with moderate to severe ulcerative colitis (abstract). Gastroenterology 2006;130(Suppl 2):A-126.
45. Hanai H, Iida T, Watanabe F, et al: Intensive granulocyte and monocyte apheresis versus intravenous prednisolone in patients with severe ulcerative colitis: a multicentre randomized controlled study (abstract). Gut 2006;55(Suppl V):A-40.
46. Sakuraba A, et al: An open-labeled trial of granulocyte and monocyte adsorption apheresis for pouchitis (abstract). Gastroenterology 2006;130(Suppl 2):A-661.
47. Matsui T, Nishimura T, Matake H, et al: Granulocytapheresis for Crohn's disease: a report on seven refractory patients. Am J Gastroenterol 2003;98:511-512.
48. Kusaka T, Fukunaga K, Ohnishi K, et al: Adsorptive monocyte- granulocytapheresis (M-GCAP) for refractory Crohn's disease. J Clin Apher 2004;19:168-173.
49. Fukuda Y, Matsui T, Suzuki Y, et al: Adsorptive granulocyte and monocyte apheresis for refractory Crohn's disease: an open multicenter prospective study. J Gastroenterol 2004;39:1158-1164.
50. Muratov V, Lundahl J, Ulfgren AK, et al: Down-regulation of interferon-γ parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study. Int J colorectal Dis 2006;21:493-504.
51. Petermann S, Rieckeheer K, Kury C, et al: Leukocytapheresis using granulocyte and monocyte adsorption apheresis in chronic active Crohn's disease. Gut 2005;54:A-177.
52. Marin I, Taxonera C, Abreu L, et al: Granulocyteapheresis in difficult-to-treat Crohn's disease: a multicenter prospective open study. Gut 2005;54:A158.
53. Tomomasa T, Kobayashi A, Kaneko H, et al: Granulocyte adsorptive apheresis for pediatric patients with ulcerative colitis. Dig Dis Sci 2003;48:750-754.
54. Ikeda H, Ishimaru H, Takayasu H, et al: Efficacy of granulocyte apheresis in pediatric patients with ulcerative colitis: a pilot study. J Pediatr Gastroenterol Nutr 2006;43:592-596.
55. Sawada K, Ohnishi K, Fukui S, et al: Leukocytapheresis therapy, performed with leukocyte removal filter for inflammatory bowel disease. J Gastroenterol 1995;30:322-329.
56. Sawada K, Ohnishi K, Kosaka T, et al: Leukocytapheresis therapy with leukocyte removal filter for inflammatory bowel disease. J Gastroenterol 1995;30(suppl 8):124-127.
57. Sawada K, Ohnishi K, Kosaka, et al: Leukocytapheresis with leukocyte removal filter as a new therapy for ulcerative colitis. Ther Apher 1997;1:207-211.
58. Andoh A, Ogawa A, Kitamura K, et al: Suppression of interleukin-1β and tumor necrosis factor-α induced inflammatory responses by leukocytapheresis therapy in patients with ulcerative colitis. J Gastroenterol 2004;39:1150-1157.
59. Noguchi M, Hiwatashi N, Hayakawa T, et al: Leukocyte removal filter-passed lymphocytes produces large amounts of interleukin-4 in immunotherapy for inflammatory bowel disease: role of bystander suppression. Ther Apher 1998;2:109-114.
60. Andoh A, Tsujikawa T, Inatomi O, et al: Leukocytapheresis therapy modulates circulating T-cell subsets in patients with ulcerative colitis. Ther Apher Dial 2005;9:270-279.
61. + monocytes in leukocytapheresis therapy for ulcerative colitis. Inflamm Bowel Dis 2007;13:284-290.
62. King C, Ilic A, Koelsch K, et al: Homeostatic expansion of T cells during immune deficiency. Cell 2004;117:265-277.
63. Kanai T, Hibi T, Watanabe M: The logics of leukocytapheresis as a natural biological therapy for inflammatory bowel disease. Expert Opin Biol Ther 2006;6:453-466.
64. Sawada K, Muto T, Shimoyama T, et al: Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des 2003;9:307-321.
65. Sawada K, Egashira A, Ohnishi K, et al: Leukocytapheresis for management of fulminant ulcerative colitis with toxic megacolon. Dig Dis Sci 2005;50:767-773.
66. Sawada K, Kusugami K, Suzuki Y, et al: Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am J Gastroenterol 2005;100:1362-1369.
67. Emmrich J, Petermann S, Nowak D, et al: Leukocytapheresis in the management of chronic active ulcerative colitis. Results of a randomized pilot trial. Dig Dis Sci 2007;52:2044-2053.
68. Kosaka T, Sawada K, Ohnishi K, et al: Effect of leukocytapheresis therapy using leukocyte removal filter in Crohn's disease. Intern Med 1999;38:102-111.
69. Hibi T, Sakuraba A: Is there a role for apheresis in gastrointestinal disorders? Nat Clin Pract Gastroenterol Hepatol 2005;2:200-201.